Gilat Satellite Networks Ltd. (NASDAQ:GILT) shares fell -1.14% in last trading session and ended the day at $3.46. GILT Gross Margin is 31.20% and its has a return on assets of -3.40%. Gilat Satellite Networks Ltd. (NASDAQ:GILT) quarterly performance is -36.04%.
On 25 September, it was reported Gilat Satellite Networks Ltd. (NASDAQ:GILT) has announced that it has signed a long-term agreement to develop and supply high-performance dual Ku/Ka-band terminals for in-flight connectivity (IFC) on commercial aircraft.
Columbia Banking System Inc. (NASDAQ:COLB) ended the last trading day at $31.41. Company weekly volatility is calculated as 2.58% and price to cash ratio as 9.57. Columbia Banking System Inc. (NASDAQ:COLB) showed a weekly performance of 1.82%.
Columbia Banking System, Inc. (NASDAQ: COLB) expects to report third quarter 2015 financial results on Thursday, October 29, 2015 at 5:00 a.m. Pacific Daylight Time. Management will discuss these results on a conference call scheduled for that afternoon at 1:00 p.m. PDT (4:00 p.m. EDT).
On 05 October, First Commonwealth Financial Corp. (NYSE:FCF) shares increased 2.82% and was closed at $9.10. FCF EPS growth in last 5 year was 32.00%. First Commonwealth Financial Corp. (NYSE:FCF) year to date (YTD) performance is 1.06%.
On 1st October, First Commonwealth Bank, the banking subsidiary of First Commonwealth Financial Corporation (NYSE: FCF), announced that it has completed its acquisition of Columbus, Ohio based First Community Bank.
Cara Therapeutics Inc. (NASDAQ:CARA) shares increased 3.35% in last trading session and ended the day at $15.10. CARA has a return on assets of -39.00%. Cara Therapeutics Inc. (NASDAQ:CARA) quarterly performance is 18.43%.
Cara Therapeutics, Inc. (NASDAQ:CARA), announced that Chief Medical Officer Joseph Stauffer, D.O., M.B.A., presented two posters at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly, held October 1-4 at the Hynes Convention Center in Boston. These posters included positive data from Cara’s Phase 2 acute pain and human abuse liability studies of CR845, the Company’s first-in-class peripherally-selective kappa opioid agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
Heidrick & Struggles International Inc. (NASDAQ:HSII) caters to the Services space. It has a net profit margin of 2.50% and weekly performance is 8.33%. On the last day of trading company shares ended up at $21.06. Heidrick & Struggles International Inc. (NASDAQ:HSII) distance from 50-day simple moving average (SMA50) is 4.26%.
Heidrick & Struggles International Inc. (NASDAQ: HSII) acquired Co Company, a London-based leadership advisory firm. The transaction closed Oct. 1, and Co Company will integrate into Heidrick & Struggles-branded Leadership Consulting.
Leave a Reply